Epidermolysis Bullosa (EB)

Current Situation

Epidermolysis Bullosa (EB) is an inherited severe skin disorder. The desease affects 500.000 individuals worldwide. EB patients, also called butterfly children, have extremely fragile skin and mucosa. even minor mechanical trauma or friction can lead to blisters, erosions and open, slowly healing wounds. The life expectancy of EB patients strongly depends on the EB subtype, the pattern of heredity, and the severity of the disease. Thus, some EB patients already die in the infancy.

 

Objective

EB is characterized devastating tissue damage which also goes hand in hand with severe inflammation. Mesenchymal stem cells offer a new chance for these patients due to their immunomodulatory and anti-inflammatory capabilities. Current literature and clinical trials confirm the clinical benefits and safety of MSCs in EB patients.

 

Procedure

At present, preliminary tests are taking place in the laboratory for the analysis of the mechanism of action of the ABCB5+ cells. So far, very good results have been achieved in the test models. (accepted: Webber et al., 2017)

All safety studies on the safety and efficacy of ABCB5+ cells have been successfully completed.

Clinical studies with allogeneic ABCB5+ cells in patients with EB are planned for early 2018.

 

Partner

  • Jakub Tolar, MD (Tulloch Chair in Stem Cell Biology, Genetics and Genomics; Director, Stem Cell Institute; Professor, Department of Pediatric Blood & Marrow Transplantation, University of Minnesota, USA)

 

« zurück

News
License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

Clinical Trial

Together with our subsidiary RHEACELL we are recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter